×
About 432,649 results
Weight change across adulthood in relation to all cause and cause specific mortality: prospective cohort study
https://www.bmj.com/content/367/bmj.l5584
BMJ Chen, C. et. al.

Oct 15th, 2019 - Objective To investigate the association between weight changes across adulthood and mortality. Design Prospective cohort study. Setting US National Health and Nutrition Examination Survey (NHANES) 1988-94 and 1999-2014. Participants 36 051 people aged 40 years or over with measured body weight and height at baseline and recalled weight at young adulthood (25 years old) and middle adul...

Association of Cardiovascular Disease With Premature Mortality in the United States
https://jamanetwork.com/journals/jamacardiology/fullarticle/2752889
JAMA Cardiology; Chen, Y. et. al.

Oct 15th, 2019 - Question How have the trends in premature mortality from cardiovascular disease (CVD) changed in the United States during 2000 to 2015 by demographics and county-level factors, including education, rurality, and the prevalence of smoking, obesity, and diabetes? Findings In this study, CVD mortality rates increased significantly among American Indian/Alaska Native individuals age 25 to 49 y...

Statins for primary prevention of cardiovascular disease
https://www.bmj.com/content/367/bmj.l5674/article-info
BMJ Byrne, P. et. al.

Oct 15th, 2019 - Statins are now the most commonly used drug in the UK and one of the most commonly used medicines in the world.12 Although prices have fallen since their patents expired, statins account for substantial drug expenditure in a context of often overstretched healthcare budgets, with estimated global sales approaching $1tn by 2020.3 Use of statins in people with established cardiovascular disease i...

U.S. FDA Approves SECUADO® (asenapine) Transdermal System, the First-and-Only Transdermal Patch for the Treatment of Adults with Schizophrenia
http://www.noven.com/PR101519.php

Oct 14th, 2019 - Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced the U.S. Food and Drug Administration (FDA) has approved SECUADO® (asenapine) transdermal system, the first-and-only transdermal patch formulation for the treatment of adults with schizophrenia.1 “As people living with schizophrenia cycle through treatments their therapeutic options ...

Philips introduces new 200mm and 150mm Stellarex 0.035” low-dose drug-coated balloons to broaden treatment options for peripheral artery disease patients
https://www.philips.com/a-w/about/news/archive/standard/news/press/2019/20191015-philips-introduces-new-200mm-and-150mm-stellarex-035-low-dose-drug-coated-balloons.html

Oct 14th, 2019 - Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today introduced two new balloons to its Stellarex 0.035” low-dose drug-coated balloon (DCB) portfolio. The new 200mm and 150mm Stellarex 0.035” low-dose DCBs have received approval from the U.S. Food and Drug Administration (FDA) for the treatment of de novo and restenotic lesions in native superficial femoral or popli...

Predicting the Risk of Postoperative Pulmonary Complications
https://www.aafp.org/afp/2019/1015/p499.html
American Family Physician;

Oct 14th, 2019 - The incidence of pulmonary complications following major surgery is estimated to be 1% to 23%, with the risk varying based on patient factors and the type of surgery.1 Postoperative pulmonary complications include pneumonia, tracheobronchitis, pulmonary edema, pulmonary embolism, atelectasis, pleural effusion, pneumothorax, bronchospasm, aspiration, respiratory failure, and acute respiratory di...

Influenza Vaccination: Updated Recommendations from ACIP
https://www.aafp.org/afp/2019/1015/p505.html

Oct 14th, 2019 - The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) has released its recommendations for routine influenza vaccination in the 2019–2020 season. Updates this year include the antigenic composition of seasonal influenza vaccines available in the United States and changes related to recent regulatory actions, including labeling changes for previousl...

Nail Changes Following a Viral Infection: Photo Quiz
https://www.aafp.org/afp/2019/1015/p497.html
American Family Physician;

Oct 14th, 2019 - A seven-year-old boy presented with abnormal growth of his fingernails that began two weeks prior. He had no other symptoms, including pain or pruritus on his hands or around his nails. He did not have fevers, chills, nausea, vomiting, or change in activity. He had hand-foot-and-mouth disease two months earlier that was diagnosed based on vesicular lesions in his mouth and on his hands and feet...

Acne Vulgaris: Diagnosis and Treatment
https://www.aafp.org/afp/2019/1015/p475.html
American Family Physician;

Oct 14th, 2019 - Acne vulgaris is the most prevalent chronic skin disease in the United States, affecting nearly 50 million people per year, mostly adolescents and young adults. Potential sequelae of acne, such as scarring, dyspigmentation, and low self-esteem, may result in significant morbidity. Typical acne lesions involve the pilosebaceous follicles and the interrelated processes of sebum production, Cutiba...

ASCO Breakthrough: Breast Cancer Gene Expression Signature May Help Predict Recurrence Postradiotherapy
https://ascopost.com/news/october-2019/breast-cancer-gene-expression-signature-may-help-to-predict-recurrence-postradiotherapy/

Oct 13th, 2019 - Researchers have identified a gene pattern that may help predict which patients with breast cancer will have early or late disease recurrence following radiation therapy. The ability to predict the timing of recurrence could change—and improve—treatment strategies and determine the length of follow-up needed. These findings were presented by Speers et al at ASCO Breakthrough: A Global Summit fo...

The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: New features and the ‘Ten Commandments’ of the 2019 Guidelines are discussed...
https://academic.oup.com/eurheartj/article/40/39/3215/5586545
European Heart Journal; Grant, P. et. al.

Oct 13th, 2019 - The prevalence of diabetes continues to increase, with 60 million thought to have diabetes in Europe in 2017 and predictions of more than 600 million individuals with diabetes worldwide by 2045. These numbers carry a huge burden of morbidity and mortality with a high prevalence of microvascular disease affecting the eyes, nerves, and kidneys and macrovascular disease leading to CV, cerebrovascu...

U.S. FDA Approves XARELTO® (rivaroxaban) to Help Prevent Blood Clots in Acutely Ill Medical Patients
https://www.jnj.com/u-s-fda-approves-xarelto-rivaroxaban-to-help-prevent-blood-clots-in-acutely-ill-medical-patients

Oct 13th, 2019 - he Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban) for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalized acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding. With the approval of this new indication, XAREL...

FDA approves new treatment for patients with migraine
https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-patients-migraine

Oct 10th, 2019 - The U.S. Food and Drug Administration today approved Reyvow (lasmiditan) tablets for the acute (active but short-term) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. Reyvow is not indicated for the preventive treatment of migraine.

Smoking & Tobacco Use For Healthcare Providers
https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease/healthcare-providers/index.html

Oct 10th, 2019 - CDC investigates outbreak of severe lung disease in patients who have recently used e-cigarette products, also known as “vaping.

Early pharmacological interventions for preventing post‐traumatic stress disorder (PTSD): a network meta‐analysis
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013443/full
The Cochrane Database of Systematic Reviews;

Oct 9th, 2019 - This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the efficacy and acceptability of pharmacological interventions for preventing post‐traumatic stress disorder (PTSD) in adults exposed to a traumatic event and to generate a clinically useful ranking of pharmacological interventions according to their efficacy and acceptability by performing a n...

Following NCCN Guidelines for Metastatic Breast Cancer Results in Lower Costs for Patients, According to New Study
https://www.nccn.org/about/news/newsinfo.aspx?NewsID=1712

Oct 9th, 2019 - A new study from the O’Neal Comprehensive Cancer Center at University of Alabama at Birmingham (UAB), published in the October 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network, finds that direct costs for metastatic breast cancer (MBC) patients increase dramatically when their treatment differs from recommendations in the NCCN Clinical Practice Guidelines in Oncology (N...

Researchers Identify Genetic Markers for Response to Radiation Therapy and Prediction of Recurrence
https://www.asco.org/about-asco/press-center/news-releases/researchers-identify-genetic-markers-response-radiation

Oct 9th, 2019 - Genetic information could help identify patients likely to respond to radiation therapy and predict when disease recurrence following radiation is likely to occur. This could help clinicians better tailor treatment strategies to individual patients to boost efficacy, while minimizing unwanted side effects. The findings come from two studies that will be presented at ASCO Breakthrough: A Global ...

Recent Trends in the Treatment and Prognosis of Male Breast Cancer
https://ascopost.com/news/october-2019/recent-trends-in-the-treatment-and-prognosis-of-male-breast-cancer/

Oct 8th, 2019 - A recent analysis published by Yadav et al in Cancer reviewed how the treatment of male breast cancer has evolved over the years 2004 to 2014. In addition, certain patient-, tumor-, and treatment-related factors were found to be linked with better survival.

Coverage from the International Congress of Parkinson’s Disease and Movement Disorders (MDS) 2019
https://www.medscape.com/viewcollection/35073

Oct 8th, 2019 - International Congress of Parkinson’s Disease and Movement Disorders (MDS) 2019: Read clinically focused news coverage of key developments from MDS 2019

FDA approves first treatment to increase pain-free light exposure in patients with a rare disorder
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-increase-pain-free-light-exposure-patients-rare-disorder

Oct 7th, 2019 - The U.S. Food and Drug Administration today granted approval to Scenesse (afamelanotide) to increase pain-free light exposure in adult patients with a history of phototoxic reactions (damage to skin) from erythropoietic protoporphyria.